Targeting oncoproteins with a positive selection assay for protein degraders-Reference-Cited by-同舟云学术

Targeting oncoproteins with a positive selection assay for protein degraders

Published:2021-02-05 Issue:6 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Koduri Vidyasagar¹^ORCID,Duplaquet Leslie¹^ORCID,Lampson Benjamin L.¹^ORCID,Wang Adam C.¹^ORCID,Sabet Amin H.¹,Ishoey Mette¹,Paulk Joshiawa¹^ORCID,Teng Mingxing²³^ORCID,Harris Isaac S.⁴⁵^ORCID,Endress Jennifer E.⁴⁵^ORCID,Liu Xiaoxi²⁶,Dasilva Ethan²⁶,Paulo Joao A.⁵^ORCID,Briggs Kimberly J.¹,Doench John G.⁷^ORCID,Ott Christopher J.¹^ORCID,Zhang Tinghu²³,Donovan Katherine A.²³^ORCID,Fischer Eric S.²³^ORCID,Gygi Steven P.⁵^ORCID,Gray Nathanael S.²³^ORCID,Bradner James⁸^ORCID,Medin Jeffrey A.⁹^ORCID,Buhrlage Sara J.²⁶,Oser Matthew G.¹¹⁰¹¹^ORCID,Kaelin William G.¹¹¹¹²^ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

2. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

3. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

4. Ludwig Cancer Center, Boston, MA 02115, USA.

5. Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

6. Linde Program in Chemical Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

7. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

8. Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

9. Departments of Pediatrics and Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

10. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

11. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA.

12. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Abstract

A new positive selection assay could enhance the discovery of compounds that degrade previously undruggable proteins.

Funder

National Institutes of Health

Howard Hughes Medical Institute

National Cancer Institute

NIGMS

American Society of Hematology

Carlsbergfondet

Damon Runyon Cancer Research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

2. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

3. Common pitfalls in preclinical cancer target validation

4. Cell Fate Control Gene Therapy Based on Engineered Variants of Human Deoxycytidine Kinase

5. Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs;ACS Chemical Biology;2024-09-12

2. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer;Cancer Cell;2024-08

3. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

4. Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB;Cell;2024-04

5. Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer;Molecular Cancer Research;2024-03-21